Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn

References

• Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473-80. doi:10.1038/nrc2394. PMID:18469827
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301-16. doi:10.1038/nri2761. PMID:20414204
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-87. doi:10.1038/nrc3236. PMID:22437872
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-8. doi:10.1016/S1359-6446(05)03638-X. PMID:16478695
   PubMed Web of Science ®Google Scholar
• Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21–22:75-83. doi:10.1016/j.ddtec.2016.09.004. PMID:27978991
   PubMedGoogle Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61-76. doi:10.1111/j.1365-2125.2009.03401.x. PMID:19660004
   PubMed Web of Science ®Google Scholar
• Zareba KM. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria. Drugs Today. 2007;43:539. doi:10.1358/dot.2007.43.8.1130446. PMID:17925885
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol Baltim Md 1950 1993;151:1235-44.
   Google Scholar
• Rehlaender BN, Cho MJ. Antibodies as carrier proteins. Pharm Res. 1998;15:1652-6. doi:10.1023/A:1011936007457. PMID:9833983
   PubMed Web of Science ®Google Scholar
• Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. mAbs. 2010;2:576-88. doi:10.4161/mabs.2.5.12833. PMID:20676036
   PubMed Web of Science ®Google Scholar
• Martin PL, Cornacoff J, Prabhakar U, Lohr T, Treacy G, Sutherland JE, Hersey S, Martin E. Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-α in Cynomolgus Macaques. J Immunotoxicol. 2005;1:131-9. doi:10.1080/15476910490894904. PMID:18958646
   PubMedGoogle Scholar
• Xiao JJ, Krzyzanski W, Wang Y-M, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ. Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys. AAPS J. 2010;12:646-57. doi:10.1208/s12248-010-9222-0. PMID:20737261
   PubMed Web of Science ®Google Scholar
• Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, Pouliquen I. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol. 2013;75:118-28. doi:10.1111/j.1365-2125.2012.04334.x. PMID:22616628
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 2010;28:1203-7. doi:10.1038/nbt.1691. PMID:20953198
   PubMed Web of Science ®Google Scholar
• Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9. J Biol Chem. 2012;287:11090-7. doi:10.1074/jbc.M111.319764. PMID:22294692
   PubMed Web of Science ®Google Scholar
• Devanaboyina SC, Lynch SM, Ober RJ, Ram S, Kim D, Puig-Canto A, Breen S, Kasturirangan S, Fowler S, Peng L, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. mAbs. 2013;5:851-9. doi:10.4161/mabs.26389. PMID:24492341
   PubMed Web of Science ®Google Scholar
• Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017;7:1080. doi:10.1038/s41598-017-01087-7. PMID:28439081
   PubMed Web of Science ®Google Scholar
• Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, Hironiwa N, et al. Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo. PLoS ONE. 2013;8:e63236. doi:10.1371/journal.pone.0063236. PMID:23667591
   PubMed Web of Science ®Google Scholar
• Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim Biophys Acta BBA - Proteins Proteomics. 2014;1844:1943-50. doi:10.1016/j.bbapap.2014.08.003. PMID:25125373
   PubMed Web of Science ®Google Scholar
• Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH Dependence of the Neonatal Fc Receptor/Immunoglobulin G Interaction Using Antibody and Receptor Variants. Biochemistry (Mosc). 1995;34:14649-57; doi:10.1021/bi00045a005
   Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-25. doi:10.1038/nri2155. PMID:17703228
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514-24. doi:10.1074/jbc.M604292200. PMID:16793771
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Maeda A, Nakai T. Antibodies with modified affinity to fcrn that promote antigen clearance [Internet]. 2016 [cited 2016 Oct 19]; Available from: http://www.google.com/patents/US20160244526.
   Google Scholar
• Yang D, Singh A, Wu H, Kroe-Barrett R. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. Anal Biochem. 2016;508:78-96. doi:10.1016/j.ab.2016.06.024. PMID:27365220
   PubMed Web of Science ®Google Scholar
• Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu J-F, Kamerud J, Ahene A, Myler H, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011;13:99-110. doi:10.1208/s12248-011-9251-3. PMID:21240643
   PubMed Web of Science ®Google Scholar
• Bonvin P, Venet S, Fontaine G, Ravn U, Gueneau F, Kosco-Vilbois M, Proudfoot AE, Fischer N. De novo isolation of antibodies with pH-dependent binding properties. mAbs. 2015;7:294-302. doi:10.1080/19420862.2015.1006993. PMID:25608219
   PubMed Web of Science ®Google Scholar
• Lee E-C, Liang Q, Ali H, Bayliss L, Beasley A, Bloomfield-Gerdes T, Bonoli L, Brown R, Campbell J, Carpenter A, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014;32:356-63. doi:10.1038/nbt.2825. PMID:24633243
   PubMed Web of Science ®Google Scholar
• Henne KR, Ason B, Howard M, Wang W, Sun J, Higbee J, Tang J, Matsuda KC, Xu R, Zhou L, et al. Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement. J Pharmacol Exp Ther. 2015;353:119-31. doi:10.1124/jpet.114.221242. PMID:25653417
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Iwayanagi Y, Maeda A, Ozeki K, Nezu J, Ishigai M, Igawa T. PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody–antigen binding model. Drug Metab Pharmacokinet. 2016;31:123-32. doi:10.1016/j.dmpk.2015.12.007. PMID:26944099
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, Yu X-Q, Oganesyan V, Dall'Acqua WF, Tsui P. pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling. J Biol Chem. 2014;290:4282-90. doi:10.1074/jbc.M114.603712. PMID:25538249
   PubMed Web of Science ®Google Scholar
• Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, Viswanathan M, Martik D, Wassaf D, Mezo A. Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015;6. doi:10.3389/fimmu.2015.00176. PMID:25954273
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34:687-709. doi:10.1007/s10928-007-9065-1. PMID:17636457
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39:67-86. doi:10.1007/s10928-011-9232-2. PMID:22143261
   PubMed Web of Science ®Google Scholar
• Prabhat P, Gan Z, Chao J, Ram S, Vaccaro C, Gibbons S, Ober RJ, Ward ES. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci. 2007;104:5889-94. doi:10.1073/pnas.0700337104. PMID:17384151
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn. J Immunol. 2004;172:2021-9. doi:10.4049/jimmunol.172.4.2021. PMID:14764666
   PubMed Web of Science ®Google Scholar
• Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. Proc Natl Acad Sci. 2004;101:11076-81. doi:10.1073/pnas.0402970101. PMID:15258288
   PubMed Web of Science ®Google Scholar
• Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J. 2012;14:850-9. doi:10.1208/s12248-012-9395-9. PMID:22956476
   PubMed Web of Science ®Google Scholar
• Gil J, Silage DA. Morphometry of pinocytotic vesicles in the capillary endothelium of rabbit lungs using automated equipment. Circ Res. 1980;47:384-91. doi:10.1161/01.RES.47.3.384. PMID:7408120
   PubMed Web of Science ®Google Scholar
• Harlow E, Lane D. Using Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press; 1999.
   Google Scholar
• Giragossian C, Vage C, Li J, Pelletier K, Piché-Nicholas N, Rajadhyaksha M, Liras J, Logan A, Calle RA, Weng Y. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos Biol Fate Chem. 2015;43:803-11. doi:10.1124/dmd.114.061713. PMID:25805881
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5. doi:10.1023/A:1018943613122. PMID:8378254
   PubMed Web of Science ®Google Scholar
• Wiśniewski JR, Ostasiewicz P, Duś K, Zielińska DF, Gnad F, Mann M. Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma. Mol Syst Biol. 2012;8:611. doi:10.1038/msb.2012.44. PMID:22968445
   PubMed Web of Science ®Google Scholar